These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33166562)

  • 1. HIV-1 gp41 genetic diversity and enfuvirtide resistance-associated mutations among enfuvirtide-naïve patients in southern China.
    Chang L; Zhao J; Guo F; Ji H; Zhang L; Jiang X; Wang L
    Virus Res; 2021 Jan; 292():198215. PubMed ID: 33166562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High prevalence of primary Enfuvirtide (ENF) resistance-associated mutations in HIV-1-infected patients in Hong Kong.
    Leung PH; Chen JH; Wong KH; Chan KC; Lam HY; Cheng VC; Yuen KY; Yam WC
    J Clin Virol; 2010 Mar; 47(3):273-5. PubMed ID: 20116329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.
    Ray N; Harrison JE; Blackburn LA; Martin JN; Deeks SG; Doms RW
    J Virol; 2007 Apr; 81(7):3240-50. PubMed ID: 17251281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 molecular epidemiology and drug resistance-associated mutations among treatment-naïve blood donors in China.
    Zhao J; Lv X; Chang L; Ji H; Harris BJ; Zhang L; Jiang X; Guo F; Hackett J; Yin P; Cloherty GA; Rodgers MA; Wang L
    Sci Rep; 2020 May; 10(1):7571. PubMed ID: 32371875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotypic analysis of the gp41 HR1 region from HIV-1 isolates from enfuvirtide-treated and untreated patients.
    Pessoa LS; Valadão AL; Abreu CM; Calazans AR; Martins AN; Azevedo SS; Couto-Fernandez JC; Azevedo MC; Tanuri A
    J Acquir Immune Defic Syndr; 2011 Aug; 57 Suppl 3():S197-201. PubMed ID: 21857318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immunodeficiency virus type 1 gp 41 mutations in proviral DNA among antiretroviral treatment-naive individuals from India.
    Sen S; Tripathy SP; Sahni AK; Gupta RM; Kapila K; Chopra GS; Chimanpure VM; Patil AA; Paranjape RS
    AIDS Res Hum Retroviruses; 2009 May; 25(5):521-3. PubMed ID: 19400735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms in the HIV-1 gp41 env gene, natural resistance to enfuvirtide (T-20) and pol resistance among pregnant Brazilian women.
    Reis MN; de Alcântara KC; Cardoso LP; Stefani MM
    J Med Virol; 2014 Jan; 86(1):8-17. PubMed ID: 24037943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
    Labrosse B; Morand-Joubert L; Goubard A; Rochas S; Labernardière JL; Pacanowski J; Meynard JL; Hance AJ; Clavel F; Mammano F
    J Virol; 2006 Sep; 80(17):8807-19. PubMed ID: 16912327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variants with different mutation patterns persist in the quasispecies of enfuvirtide-resistant HIV-1 population during and after treatment in vivo.
    Trabaud MA; Cotte L; Labernardière JL; Lebel-Binay S; Icard V; Tardy JC; Trepo C; Andre P
    J Acquir Immune Defic Syndr; 2007 Oct; 46(2):134-44. PubMed ID: 17621239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.
    Mink M; Mosier SM; Janumpalli S; Davison D; Jin L; Melby T; Sista P; Erickson J; Lambert D; Stanfield-Oakley SA; Salgo M; Cammack N; Matthews T; Greenberg ML
    J Virol; 2005 Oct; 79(19):12447-54. PubMed ID: 16160172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic analysis and natural polymorphisms in HIV-1 gp41 isolates from Maputo City, Mozambique.
    Ismael N; Bila D; Mariani D; Vubil A; Mabunda N; Abreu C; Jani I; Tanuri A
    AIDS Res Hum Retroviruses; 2014 Jun; 30(6):603-9. PubMed ID: 24188582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide.
    Ray N; Blackburn LA; Doms RW
    J Virol; 2009 Apr; 83(7):2989-95. PubMed ID: 19153234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of HIV-1 non-B subtypes and recombinant variants to Enfuvirtide.
    Holguín A; Faudon JL; Labernardière JL; Soriano V
    J Clin Virol; 2007 Feb; 38(2):176-80. PubMed ID: 17196877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates.
    Sista PR; Melby T; Davison D; Jin L; Mosier S; Mink M; Nelson EL; DeMasi R; Cammack N; Salgo MP; Matthews TJ; Greenberg ML
    AIDS; 2004 Sep; 18(13):1787-94. PubMed ID: 15316339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The genotype distribution, infection stage and drug resistance mutation profile of human immunodeficiency virus-1 among the infected blood donors from five Chinese blood centers, 2014-2017.
    Liang S; Liu Z; Wang S; Liu J; Shi L; Mao W; Liu C; Wan J; Zhu L; Huang M; Liu Y; Wang J; Ness P; Shan H; Zeng P; He M
    PLoS One; 2020; 15(12):e0243650. PubMed ID: 33347449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIVfird: A Tool for Detection of Resistance to Fusion Inhibitor Drugs in HIV-1 Sequences.
    Barreto Vasconcelos AL; Monteiro-Cunha JP
    AIDS Res Hum Retroviruses; 2019 Oct; 35(10):941-947. PubMed ID: 31280582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of HIV type 1 gp41 sequences in diverse HIV type 1 strains.
    Eshleman SH; Hudelson SE; Bruce R; Lee T; Owens MR; Hackett J; Swanson P; Devare SG; Marlowe N
    AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1593-8. PubMed ID: 18160019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype.
    Cunyat F; Marfil S; García E; Svicher V; Pérez-Alvárez N; Curriu M; Perno CF; Clotet B; Blanco J; Cabrera C
    Retrovirology; 2012 Feb; 9():15. PubMed ID: 22333046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of HIV type 1 gp41 and enfuvirtide susceptibility among men in the United States who were HIV infected prior to availability of HIV entry inhibitors.
    Hudelson SE; Marlowe N; Huang W; Bruce R; Church JD; Husnik M; Donnell D; Coates T; Jackson JB; Chesney M; Koblin B; Eshleman SH
    AIDS Res Hum Retroviruses; 2009 Jul; 25(7):701-5. PubMed ID: 19552592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev.
    Svicher V; Alteri C; D'Arrigo R; Laganà A; Trignetti M; Lo Caputo S; Callegaro AP; Maggiolo F; Mazzotta F; Ferro A; Dimonte S; Aquaro S; di Perri G; Bonora S; Tommasi C; Trotta MP; Narciso P; Antinori A; Perno CF; Ceccherini-Silberstein F
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2816-23. PubMed ID: 19124665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.